Trial Profile
Use of a Wakefulness-Promoting Agent (Armodafinil) Combined With Neuro-rehabilitation to Improve Neurological Recovery and to Reduce the Incidence of Disability in Patients Who Suffered a Stroke
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Armodafinil (Primary)
- Indications Cerebral haemorrhage; Cerebral infarction; Paresis; Stroke
- Focus Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 27 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2014 New trial record